Talayeh S Ghezelayagh1, Kathryn P Pennington2, Barbara M Norquist2, Nithisha Khasnavis3, Marc R Radke2, Mark R Kilgore4, Rochelle L Garcia4, Ming Lee2, Ronit Katz2, Kimberly K Leslie5, Rosa Ana Risques4, Elizabeth M Swisher2. 1. Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. Electronic address: tghezel@uw.edu. 2. Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA. 3. Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA; Department of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 4. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. 5. Department of Obstetrics and Gynecology and the Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Abstract
OBJECTIVES: Mutations in the TP53 tumor suppressor gene are common in ovarian carcinoma (OC) but their impact on outcomes is controversial. We sought to define the relationship of TP53 mutations to cancer outcomes and their interactions with co-occurrent BRCA1 or BRCA2 (BRCA) mutations, comparing three different TP53 mutation classification schemes. METHODS: We performed next generation sequencing on 393 cases of OC prospectively followed for survival. TP53 mutations were classified according to three schemes termed Structural, Functional, and Hotspot. Mutation distribution was compared between cases with and without BRCA mutations. In a subset of 281 cases of high grade serous carcinoma (HGSC), overall survival was compared using Kaplan-Meier curves, logrank testing, and multivariate Cox regression analysis, both stratified and adjusted for BRCA mutation status. Multivariate logistic regression was used to analyze the effects of TP53 mutation type on platinum resistance. RESULTS: TP53 mutations were identified in 76.8% of the total cohort (n = 302/393) and 87.9% of HGSC (n = 247/281). Cases with BRCA mutations demonstrated significantly higher TP53 mutation frequency overall (n = 84/91, 92.3% vs. n = 218/302, 72.2%, p < 0.001). TP53 mutations were not associated with overall survival, even when stratified by BRCA mutation. TP53 mutations were associated with platinum sensitivity, even after adjusting for BRCA mutation status (OR 0.41, p = 0.048). The choice of TP53 mutation classification scheme was not found to alter any significant outcome. CONCLUSIONS: BRCA mutations significantly co-occur with TP53 mutations. After adjusting for BRCA mutations, TP53 mutations are associated with platinum sensitivity, and this effect is not dependent on TP53 mutation type.
OBJECTIVES: Mutations in the TP53 tumor suppressor gene are common in ovarian carcinoma (OC) but their impact on outcomes is controversial. We sought to define the relationship of TP53 mutations to cancer outcomes and their interactions with co-occurrent BRCA1 or BRCA2 (BRCA) mutations, comparing three different TP53 mutation classification schemes. METHODS: We performed next generation sequencing on 393 cases of OC prospectively followed for survival. TP53 mutations were classified according to three schemes termed Structural, Functional, and Hotspot. Mutation distribution was compared between cases with and without BRCA mutations. In a subset of 281 cases of high grade serous carcinoma (HGSC), overall survival was compared using Kaplan-Meier curves, logrank testing, and multivariate Cox regression analysis, both stratified and adjusted for BRCA mutation status. Multivariate logistic regression was used to analyze the effects of TP53 mutation type on platinum resistance. RESULTS: TP53 mutations were identified in 76.8% of the total cohort (n = 302/393) and 87.9% of HGSC (n = 247/281). Cases with BRCA mutations demonstrated significantly higher TP53 mutation frequency overall (n = 84/91, 92.3% vs. n = 218/302, 72.2%, p < 0.001). TP53 mutations were not associated with overall survival, even when stratified by BRCA mutation. TP53 mutations were associated with platinum sensitivity, even after adjusting for BRCA mutation status (OR 0.41, p = 0.048). The choice of TP53 mutation classification scheme was not found to alter any significant outcome. CONCLUSIONS: BRCA mutations significantly co-occur with TP53 mutations. After adjusting for BRCA mutations, TP53 mutations are associated with platinum sensitivity, and this effect is not dependent on TP53 mutation type.
Authors: Kathryn P Pennington; Tom Walsh; Maria I Harrell; Ming K Lee; Christopher C Pennil; Mara H Rendi; Anne Thornton; Barbara M Norquist; Silvia Casadei; Alexander S Nord; Kathy J Agnew; Colin C Pritchard; Sheena Scroggins; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher Journal: Clin Cancer Res Date: 2013-11-15 Impact factor: 12.531
Authors: Chae Young Han; David A Patten; Seung Gee Lee; Robin J Parks; David W Chan; Mary-Ellen Harper; Benjamin K Tsang Journal: Mol Carcinog Date: 2019-09-04 Impact factor: 4.784
Authors: Xi Wang; Amber A El-Halaby; Hengwei Zhang; Qi Yang; Todd S Laughlin; Paul G Rothberg; Kristin Skinner; David G Hicks Journal: Hum Pathol Date: 2017-04-21 Impact factor: 3.466
Authors: R Salani; R J Kurman; R Giuntoli; G Gardner; R Bristow; T-L Wang; I-M Shih Journal: Int J Gynecol Cancer Date: 2007-08-10 Impact factor: 3.437
Authors: Tuomas Tikkanen; Bernard Leroy; Jean Louis Fournier; Rosa Ana Risques; Jitka Malcikova; Thierry Soussi Journal: Hum Mutat Date: 2018-05-17 Impact factor: 4.878
Authors: Pavla Brachova; Samuel R Mueting; Matthew J Carlson; Michael J Goodheart; Anna M Button; Sarah L Mott; Donghai Dai; Kristina W Thiel; Eric J Devor; Kimberly K Leslie Journal: Int J Oncol Date: 2014-11-11 Impact factor: 5.650
Authors: Martin Köbel; Anna M Piskorz; Sandra Lee; Shuhong Lui; Cecile LePage; Francesco Marass; Nitzan Rosenfeld; Anne-Marie Mes Masson; James D Brenton Journal: J Pathol Clin Res Date: 2016-07-13
Authors: Musaffe Tuna; Zhenlin Ju; Kosuke Yoshihara; Christopher I Amos; Janos L Tanyi; Gordon B Mills Journal: Br J Cancer Date: 2019-11-29 Impact factor: 7.640